Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?

Chest

Volumn 116, Issue 3, 1999, Pages 715-720

  Diot, Elisabeth ^a   Giraudeau, Bruno ^b   Diot, Patrice ^a   Degenne, Danielle ^a   Ritz, Laurence ^a   Guilmot, Jean Louis ^a   Lemarié, Etienne ^a  

^a CHU BRETONNEAU   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Anti topoisomerase; Pulmonary involvement; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; DNA TOPOISOMERASE; DNA TOPOISOMERASE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMAGE ANALYSIS; LUNG FIBROSIS; LUNG FUNCTION TEST; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

EID: 0032821887     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.3.715     Document Type: Article

References (32)

1. 1 Le Roy EC, Krieg T, Black C, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205
2. 2 Tan EM, Rodnan GP, Garcia I, et al. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980; 23:617-625
3. 3 Catoggio LJ, Bernstein RM, Black CM, et al. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983; 42:23-37
4. 4 Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31:196-203
5. 5 Giordano M, Valentini G, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rhumatol 1986; 13:911-16
6. 6 Shero J, Bordwell B, Rothfield NF, et al. High titers of antibodies to topoisomerase I (Scl70) in sera from scleroderma patients. Science 1986; 231:737-740
7. 7 Jarzabek-Chorzelska M, Blaszezyk M, Jablonska S, et al. Scl 70 antibody: a specific marker of systemic sclerosis. Br J Dermatol 1986; 115:393-401
8. 8 Aeschlimann A, Meyer O, Bourgeois P, et al. Anti-Scl70-antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlation. Ann Rheum Dis 1989; 48:992-997
9. 9 Parodi A, Puiatti P, Rebora A. Serological profile as prognostic clues for progressive systemic scleroderma: the Italian experience. Dermatologica 1991; 183:15-20
10. 10 Fritzler MJ, Kinsella TD, Garbutt E. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980; 69:520-526
11. 11 Miller MH, Littlejohn GO, Davidson A, et al. The clinical significance of anticentromere antibody. Br J Rheumatol 1987; 26:17-21
12. 12 Briggs DC, Vanghan RW, Welsh KI, et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338:661-662
13. 13 Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high resolution CT versus radiography. Radiology 1990; 176:755-759
14. 14 Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992; 47:508-512
15. 15 Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-590
16. 16 Quanjer PhH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J 1993; 6(suppl 16):5-40
17. 17 Cotes JE, Chinn DJ, Quanjer PhH, et al. Standardization of the measurement of transfer factor (diffusion capacity). Eur Respir J 1993; 6(suppl 16):41-52
18. 18 Keogh BA, Crystal RG. Clinical significance of pulmonary function tests: pulmonary function tests in interstitial lung disease; what does it tell us? Chest 1980; 78:856-865
19. 19 Diot E, Diot P, Valat C, et al. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with systemic sclerosis. Eur Respir J 1995; 8:1559-1565
20. 20 Wells AU, Rubens MB, Du Bois RM, et al. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. Am J Roentgenol 1993; 161:1159-1165
21. 21 Warrick JH, Bhalla M, Schabel SI, et al. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991; 18:1520-1528
22. 22 Valat C, Diot E, Diot P. Serum III procollagen is predictive of lung involvement in systemic sclerosis, but not serum I procollagen. Clin Exp Rheumatol 1998; 16:517-518
23. 23 Diot E, Boissinot E, Asquier E, et al. Relationship between abnormalities on high resolution computed tomography and pulmonary function in systemic sclerosis. Chest 1998; 114: 1623-1629
24. 24 Fleiss JL, Shrout PE. Approximate interval estimation for a certain intraclass correlation coefficient. Psychometrika 1978; 43:259-262
25. 25 Albert A, Anderson JA. On the existence of maximum likelihood estimates in logistic regression models. Biometrika 1984; 71:1-10
26. 26 Vazquez-Abad D, Russell CA, Cusick SM, et al. Longitudinal study of anticentromere and antitopoisomerase-I isotypes. Clin Immunol Immunopathol 1995; 74:257-270
27. 27 Ruffati A, Calligaro A, Ferri C, et al. Association of anti-centromere and anti-Scl70 antibodies in scleroderma: report of two cases. J Clin Lab Immunol 1985; 16:227-279
28. 28 Kuwana M, Kaburaki J, Okano Y, et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 1:75-83
29. 29 D'Angelo W, Fries J, Masi A, et al. Pathologic observations in scleroderma (scleroderma). Am J Med 1969; 46:428-440
30. 30 Weaver AL, Diverties MB, Titus JL. Pulmonary scleroderma. Dis Chest 1968; 54:490-498
31. 31 Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20:838-844
32. 32 Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet 1996; 347:1453-1458